Arecor Therapeutics
plc
("Arecor"
or the "Company")
ARECOR ESTABLISHES
PARTNERSHIP WITH BIOPHARMACEUTICAL COMPANY TO DEVELOP NOVEL
FORMULATION OF PEPTIDE THERAPY
-
Partner to fund
development work with option to acquire rights to proprietary
formulation under Arecor's technology licensing
model
Cambridge, UK,
12 March 2025: Arecor Therapeutics plc (AIM:
AREC), the biopharmaceutical company advancing today's therapies to
enable healthier lives, today announces a formulation development
collaboration with a clinical-stage biopharmaceutical company
developing peptide therapies. The partnership aims to develop a
differentiated formulation of the partner's peptide therapy using
Arecor's proprietary formulation technology platform,
Arestat™. The collaboration reinforces Arecor's expertise
developing novel formulations of peptide therapeutics.
Under the terms of the agreement, the partner
will fund Arecor's development activities with the option to
license rights to the new proprietary formulation and associated
intellectual property to further develop and commercialise the
product.
Arecor has an excellent track record developing
challenging therapeutic peptide product profiles using its Arestat™
technology. Within the Company's broader product
portfolio, Arecor continues to progress the potential of its
Arestat™ platform to enable oral peptide delivery, through its
initial oral glucagon-like peptide-1 (GLP-1) receptor agonist
programme.
The global peptide therapeutics market is
projected to reach more than $100 billion by 2034 growing at a CAGR
of 10.8% 1, driven by peptide therapeutics' strong
efficacy and selectivity towards different receptors on target
cells, the rise of endocrine and metabolic diseases, and
technological advancements in the field.
Sarah Howell,
Chief Executive Officer of Arecor, said:
"Peptides are an increasingly important class of
therapeutics to treat a wide range of chronic conditions. Arecor
has significant expertise in developing novel formulations of
therapeutic peptides to address unmet patient needs in this large
and growing market. This collaboration further validates our
leadership in this field."
-ENDS-
References
1.
Future Market Insights:
Peptide Therapeutics Market Outlook from 2024 to
2034
For more
information, please contact:
|
Arecor
Therapeutics plc
|
www.arecor.com
|
|
Dr Sarah Howell, Chief Executive
Officer
|
Tel: +44 (0) 1223 426060
Email: info@arecor.com
|
|
David Ellam, Interim Chief Financial
Officer
|
Tel: +44 (0) 1223 426060
Email: info@arecor.com
|
|
|
|
|
Singer Capital
Markets Advisory LLP (NOMAD and Joint Broker)
|
|
|
Phil Davies, Sam Butcher
|
Tel: +44 (0) 20 7496 3000
|
|
|
|
|
WG Partners
LLP (Joint Broker)
|
|
|
Nigel Barnes, Satheesh Nadarajah
David Wilson, Claes Spang
|
Tel: +44 (0) 20 3705 9321
|
|
|
|
|
ICR
Healthcare
|
|
|
Chris Gardner, David Daley, Lindsey
Neville
|
Tel: +44 (0) 20 3709 5700
Email: arecor@icrhealthcare.com
|
|
|
|
Notes to
Editors
About
Arecor
Arecor Therapeutics plc is a globally focused
biopharmaceutical company transforming patient care by bringing
innovative medicines to market through the enhancement of existing
therapeutic products. By applying our innovative proprietary
technology platform, Arestat™, we are developing an internal
portfolio of proprietary products in diabetes and other
indications, as well as working with leading pharmaceutical and
biotechnology companies to deliver therapeutic products. The
Arestat™ platform is supported by an extensive patent
portfolio. For further details please see our website,
www.arecor.com
